Tafoxiparin is protected by several patent families

Tafoxiparin, Dilafor´s drug product candidate, is protected by several patent families, with basic patent expiries in 2023-2034. A substance patent has been granted in the US, and applications are pending in all major territories for different aspects of the drug product candidate.


“I am delighted that my 40 years’ preclinical and clinical research have reached this significant milestone. There is a great medical need for new treatments to address protracted labor and I hope that tafoxiparin will make a difference for all these pregnant women.”

Professor Gunvor Ekman Ordeberg, Founder and CMO at start of phase IIb